The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception.
about
Management of inflammatory bowel disease in pregnancyManagement of rheumatoid arthritis during pregnancy: challenges and solutionsInfertility in men with inflammatory bowel diseaseInflammatory bowel diseases and human reproduction: a comprehensive evidence-based reviewFertility and pregnancy in the patient with inflammatory bowel disease.Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death.Pregnancy and breastfeeding in patients with Crohn's disease.Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease.Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive.Use of Immunomodulators and Biologics Before, During, and After Pregnancy.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Immunosuppressants and Male Reproduction.Infliximab and semen quality in men with inflammatory bowel disease.The associations of thiopurines with male fertility and paternally exposed offspring: a systematic review and meta-analysis.Population Based Paternity Rate and Partner Birth Outcomes Among Utah Men With Inflammatory Bowel Disease.Paternal drug use: before and during pregnancy.
P2860
Q26865914-E2759EA9-C2B8-4E93-AD66-996BD8C2E1CDQ28068678-23B2CE10-41B4-43FB-A4AC-2B089AC446E8Q28079553-ACFF8C06-432D-4D52-8E98-6BE69B23A3CCQ28388274-3311DB4D-B5EB-4BFF-824D-A22A7E796598Q35760599-7AF97CBB-50E4-439E-A4C5-0E9DCC07307BQ36291554-A6E78601-946D-4A98-AD8D-1FBB4693AC49Q37073424-CC20E9FD-0E2C-4BCA-848C-FAA13BA24DEDQ37995572-2B468CCC-270C-4B14-8EAA-3519B8486043Q38370759-9F04A8BE-EEF6-4CC5-81D3-92664C39A59CQ38601306-CA901400-35F2-450D-B9C4-F8ADC3A57284Q39435409-039699BB-9200-45E8-AFD0-2EF1A18FB9BCQ46236864-F5AE2A91-B060-4959-B7BB-71CCFB975A22Q46478936-B7C9011F-8D81-4F1F-9FAE-1246FD588F14Q47391247-E735CC33-5765-4D4B-A8DA-710B755EB638Q47621577-9DDDE25E-E31A-4A64-BA51-13AF598E536BQ47992724-D969E58F-A625-4AEE-9B56-DC8DF4D8C8A6
P2860
The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The risk of congenital abnorma ...... captopurine before conception.
@en
The risk of congenital abnorma ...... captopurine before conception.
@nl
type
label
The risk of congenital abnorma ...... captopurine before conception.
@en
The risk of congenital abnorma ...... captopurine before conception.
@nl
prefLabel
The risk of congenital abnorma ...... captopurine before conception.
@en
The risk of congenital abnorma ...... captopurine before conception.
@nl
P2093
P2860
P1476
The risk of congenital abnorma ...... captopurine before conception.
@en
P2093
Jacobsen J
Pedersen L
Rasmussen SN
Sørensen HT
P2860
P304
P356
10.1111/J.1365-2036.2004.01889.X
P407
P577
2004-03-01T00:00:00Z